

Xiaosong Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2412125/publications.pdf>

Version: 2024-02-01

92
papers

1,879
citations

430874

18
h-index

289244

40
g-index

100
all docs

100
docs citations

100
times ranked

3056
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, e147-e156.	2.4	1
2	Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy. <i>Scientific Reports</i> , 2022, 12, 2169.	3.3	2
3	Association of machine learning ultrasound radiomics and disease outcome in triple negative breast cancer.. <i>American Journal of Cancer Research</i> , 2022, 12, 152-164.	1.4	0
4	Editorial: Metabolic Abnormalities and Breast Cancer: Challenges From Bench to Bedside. <i>Frontiers in Oncology</i> , 2022, 12, 890810.	2.8	0
5	Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	4
6	Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component. <i>British Journal of Cancer</i> , 2021, 124, 975-981.	6.4	2
7	Reply to Letter to Editor: “HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?” <i>Breast</i> , 2021, 55, 137.	2.2	0
8	Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199667.	3.2	8
9	Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 636266.	2.8	4
10	A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age. <i>Journal of Translational Medicine</i> , 2021, 19, 75.	4.4	3
11	Outcome of Liver Transplantation for Neonatal-onset Citrullinemia Type I. <i>Transplantation</i> , 2021, 105, 569-576.	1.0	6
12	Abstract PS1-53: Does the axilla surgical management for limited sentinel lymph nodes involvement vary between total mastectomy and breast-conserving surgery. , 2021, , .		0
13	Abstract PS18-22: Association of molecular biomarkers heterogeneity and treatment pattern, disease outcomes in multifocal or multicentric breast cancer patients. , 2021, , .		0
14	Abstract PS4-28: Efficacy of adjuvant chemotherapy stratified by age and the 21 gene recurrence score in estrogen receptor positive breast cancer. , 2021, , .		0
15	Abstract PS9-10: Can composite risk model help clinicians make adjuvant ovary function suppression decision for breast cancer patients. , 2021, , .		0
16	CRISPR-cas9 Screening Identified Lethal Genes Enriched in Cell Cycle Pathway and of Prognosis Significance in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 646774.	3.7	6
17	Comprehensive Association Analysis of 21-Gene Recurrence Score and Obesity in Chinese Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 619840.	2.8	5
18	A novel metabolic gene signature-based nomogram to predict overall survival in breast cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 367-367.	1.7	7

#	ARTICLE	IF	CITATIONS
19	Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 629666.	2.8	43
20	Inhibition of the FACT Complex Targets Aberrant Hedgehog Signaling and Overcomes Resistance to Smoothed Antagonists. <i>Cancer Research</i> , 2021, 81, 3105-3120.	0.9	9
21	A New k\$-Nearest Neighbors Algorithm for Learning from Multiple Experts' Uncertain Decisions. , 2021, , .		0
22	Identification of Ten Mitosis Genes Associated with Tamoxifen Resistance in Breast Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3611-3624.	2.0	1
23	Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer. <i>Breast</i> , 2021, 57, 71-79.	2.2	8
24	Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer. <i>BMC Cancer</i> , 2021, 21, 707.	2.6	1
25	Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients. <i>BMC Cancer</i> , 2021, 21, 807.	2.6	1
26	Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 638619.	2.8	9
27	Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis. <i>Cancer Management and Research</i> , 2021, Volume 13, 6279-6289.	1.9	3
28	21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients. <i>Frontiers in Endocrinology</i> , 2021, 12, 725161.	3.5	2
29	A Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e27576.	4.3	13
30	Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer. <i>Cancer Medicine</i> , 2021, 10, 7921-7933.	2.8	12
31	Predictors of Nodal Pathological Complete Response in Asian Women with Stage II-III Node-Positive Breast Cancer. <i>Oncology</i> , 2021, 99, 359-364.	1.9	2
32	Prognostic Factors and Surgery for Breast Cancer Patients With Locoregional Recurrence: An Analysis of 5,202 Consecutive Patients. <i>Frontiers in Oncology</i> , 2021, 11, 763119.	2.8	3
33	Distribution and influence of the 21-gene recurrence score on chemotherapy decision-making in special type of breast cancer.. <i>American Journal of Cancer Research</i> , 2021, 11, 6188-6199.	1.4	0
34	Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 843-849.	1.0	5
35	Sonography with vertical orientation feature predicts worse disease outcome in triple negative breast cancer. <i>Breast</i> , 2020, 49, 33-40.	2.2	13
36	ASO Author Reflections: Core Needle Biopsy and Hormonal Receptor Retesting in Breast Cancer: Controversy and Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 731-732.	1.5	0

#	ARTICLE	IF	CITATIONS
37	A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis. <i>BMC Cancer</i> , 2020, 20, 663.	2.6	13
38	Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes. <i>Cancer Medicine</i> , 2020, 9, 6173-6185.	2.8	6
39	HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab. <i>Breast</i> , 2020, 54, 235-241.	2.2	10
40	Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1315.	2.8	3
41	Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 193-202.	2.5	11
42	<p>Biomarkers of Insulin and the Insulin-Like Growth Factor Axis in Relation to Breast Cancer Risk in Chinese Women</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8027-8036.	2.0	5
43	A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1335.	2.8	2
44	Associations Between Circulating Insulin-Like Growth Factor 1 and Mortality in Women With Invasive Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1384.	2.8	7
45	Adipocytes promote breast tumorigenesis through TAZ-dependent secretion of Resistin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 33295-33304.	7.1	37
46	Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis. <i>Journal of Cancer</i> , 2020, 11, 6916-6924.	2.5	8
47	Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?. <i>Frontiers in Oncology</i> , 2020, 10, 708.	2.8	2
48	A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093267.	3.2	18
49	Compliance with multidisciplinary team recommendations and disease outcomes in early breast cancer patients: An analysis of 4501 consecutive patients. <i>Breast</i> , 2020, 52, 135-145.	2.2	11
50	Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients. <i>Journal of Cancer</i> , 2020, 11, 2602-2609.	2.5	0
51	Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score. <i>Journal of Cancer</i> , 2020, 11, 2509-2517.	2.5	1
52	Single-cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy. <i>Cancer Communications</i> , 2020, 40, 329-344.	9.2	110
53	Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients. <i>Scientific Reports</i> , 2020, 10, 7029.	3.3	14
54	IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 550.	2.8	11

#	ARTICLE	IF	CITATIONS
55	A Decision Support System with Intelligent Recommendation for Multi-disciplinary Medical Treatment. <i>ACM Transactions on Multimedia Computing, Communications and Applications</i> , 2020, 16, 1-23.	4.3	10
56	Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30. <i>Oncology Letters</i> , 2020, 20, 1545-1556.	1.8	4
57	Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study. <i>Cancer Research and Treatment</i> , 2020, 52, 671-679.	3.0	5
58	Weight Gain during Neoadjuvant Chemotherapy is Associated with Worse Outcome among the Patients with Operable Breast Cancer. <i>Journal of Breast Cancer</i> , 2019, 22, 399.	1.9	10
59	21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes. <i>Scientific Reports</i> , 2019, 9, 13123.	3.3	13
60	Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24. <i>Nature Communications</i> , 2019, 10, 4353.	12.8	193
61	<p>A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3371-3379.	1.9	13
62	Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample. <i>Annals of Surgical Oncology</i> , 2019, 26, 2779-2786.	1.5	13
63	Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1877-1886.	2.5	21
64	The Effects of Liver Transplantation in Children With Niemann-Pick Disease Type B. <i>Liver Transplantation</i> , 2019, 25, 1233-1240.	2.4	13
65	Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer. <i>Journal of Cancer</i> , 2019, 10, 1110-1116.	2.5	9
66	Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era. <i>World Journal of Surgical Oncology</i> , 2019, 17, 37.	1.9	18
67	Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?. <i>European Journal of Cancer</i> , 2018, 89, 9-18.	2.8	20
68	The impact of surgical excision of the primary tumor in stage IV breast cancer on survival: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 11816-11823.	1.8	17
69	Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen. <i>Journal of Breast Cancer</i> , 2018, 21, 277.	1.9	7
70	Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study. <i>Journal of Cancer</i> , 2018, 9, 3216-3224.	2.5	9
71	A nomogram to predict adjuvant chemotherapy recommendation in breast cancer patients with intermediate recurrence score. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 222-230.	2.2	5
72	Can Clinically Node-Negative Breast Cancer Patients with Suspicious Axillary Lymph Nodes at Ultrasound But Negative Fine-Needle Aspiration Be Approached as Having Node-Negative Disease?. <i>Annals of Surgical Oncology</i> , 2017, 24, 1874-1880.	1.5	6

#	ARTICLE	IF	CITATIONS
73	Danggui Buxue Decoction, a Classical Formula of Traditional Chinese Medicine, Fails to Prevent Myelosuppression in Breast Cancer Patients Treated With Adjuvant Chemotherapy: A Prospective Study. <i>Integrative Cancer Therapies</i> , 2017, 16, 406-413.	2.0	14
74	A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer. <i>Translational Oncology</i> , 2017, 10, 988-997.	3.7	16
75	Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. <i>Oncotarget</i> , 2017, 8, 38706-38716.	1.8	31
76	Analysis of factors related to adjuvant chemotherapy decision in early breast cancer patients with intermediate recurrence score.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12032-e12032.	1.6	0
77	A Multi-disciplinary Medical Treatment Decision Support System with intelligent treatment recommendation. , 2016, , .		2
78	Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. <i>Tumor Biology</i> , 2016, 37, 9825-9835.	1.8	52
79	Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 71, 12-23.	2.8	22
80	Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer. <i>Tumor Biology</i> , 2016, 37, 4135-4142.	1.8	34
81	The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0152500.	2.5	219
82	Biologic behavior and long-term outcomes of breast ductal carcinoma <i>in situ</i> with microinvasion. <i>Oncotarget</i> , 2016, 7, 64182-64190.	1.8	34
83	Prognostic and predictive value of Ki-67 in triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 31079-31087.	1.8	34
84	Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 822.	2.6	34
85	Breast Cancer: Diffusion Kurtosis MR Imaging's Diagnostic Accuracy and Correlation with Clinical-Pathologic Factors. <i>Radiology</i> , 2015, 277, 46-55.	7.3	196
86	Effect of curcumin on lapatinib sensitivity and lapatinib resistance associated EMT and stem-like phenotype in HER2 positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11594-e11594.	1.6	1
87	The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e115103.	2.5	182
88	A novel long non-coding RNA-ARA: Adriamycin Resistance Associated. <i>Biochemical Pharmacology</i> , 2014, 87, 254-283.	4.4	100
89	Association of epithelial-mesenchymal transition with lapatinib resistance through multiple pathways activation in HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11579-e11579.	1.6	3
90	Effect of cancer-associated fibroblasts on trastuzumab resistance by activating multiple pathways in HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11587-e11587.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer. <i>BMC Cancer</i> , 2013, 13, 390.	2.6	52
92	Measuring β -tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer. <i>Cancer Science</i> , 2012, 103, 262-268.	3.9	23